| Literature DB >> 35702290 |
Faezeh Ghanbari-Gohari1, Seyed Mohammad Mousavi1,2, Ahmad Esmaillzadeh1,2,3.
Abstract
This study aimed to quantitatively summarize earlier findings on the association between whole grain (WG) intake and type 2 diabetes (T2D) risk. We searched related keywords on PubMed/Medline, Scopus, and Google Scholar up to October 2021. Prospective observational studies investigating the association between WG intake and risk of T2D were included. The random-effects model calculates the summary relative risks by contrasting categories and linear and nonlinear dose-response associations. Eleven prospective cohort studies, including 463,282 participants and 37,249 type 2 diabetes incidents, were analyzed. The pooled relative risk (RR) for the highest versus the lowest WG intake category indicated a 21% decrease in T2D risk (95% confidence interval (CI): 0.73-0.85, I 2 = 77%). Each additional 50 grams WG consumption per day was associated with a 23% reduced risk of T2D. The nonlinear association of WG and T2D revealed that 60 grams WG intake per day would give the highest benefit to prevent T2D (Pnonlinearity < 0.001). The findings were not affected by any individual study. No evidence of publication bias was documented. In conclusion, a high intake of WG was associated with a lower risk of T2D. Randomized controlled trials are needed to confirm our results.Entities:
Keywords: diabetes mellitus; meta‐analysis; systematic review; whole grain
Year: 2022 PMID: 35702290 PMCID: PMC9179146 DOI: 10.1002/fsn3.2811
Source DB: PubMed Journal: Food Sci Nutr ISSN: 2048-7177 Impact factor: 3.553
FIGURE 1Flowchart of the number of studies identified and selected into the meta‐analysis
General characteristics of the prospective cohort studies included in the meta‐analysis of whole grain intake and risk of type 2 diabetes
| First Author. Year | Country | Age (range) | Sample size | Follow‐up duration (years) | Cohort name | Cases | Exposure | Dietary assessment | Comparison | HR (95% CI) (high versus low category) | Adjustments | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Meyer et al. ( | United States | 55–69 | F:35,988 | 6 | IWHS | 1141 | WG | Baseline FFQ | Q5 versus Q1 | 0.79 (0.65, 0.96) | 1, 4, 5, 6, 8, 17, 22, 25 | 7 |
| Montonen et al. ( | Finland | 40–69 | M/F:4316 | 10 | FMC | 156 | WG | Baseline FFQ | Q4 versus Q1 | 0.65 (0.36, 1.18) | 1, 2, 4, 5, 24, 25, 32 | 8 |
| Van Dam et al. ( | United States | 21–69 | F:41,186 | 8 | BWHS | 1964 | WG | Repeated FFQ | C4 versus C1 | 0.82 (0.71–0.94) | 1, 4, 5, 6, 11, 14, 17, 25, 26, 29, 30, 31 | 7 |
| Fisher et al. ( | Germany | 35–65 | M/F:2318 | 7 | EPIC‐Postdom | 724 | WG | Baseline FFQ | per 50g/day portion | CC genotype: 0.86 (0.75, 0.99) CT+TT genotype: 1.08 (0.96, 1.23) | 1, 2, 4, 5, 6, 10, 17, 21, 23, 26, 28, 29,31 | 5 |
| Wirström et al. ( | Sweden | 35–56 | F/M:4941 | 8–10 | – | 165 | WG | Repeated FFQ | C3 versus C1 | 0.71(0.48,1.04) | 1, 2, 4, 5, 9, 14, 17, 20 | 6 |
| Parker et al. ( | United States | 50–79 | F:72,215 | 7.9 | WHI | 3465 | WG | Repeated FFQ | C6 versus C1 | 0.75 (0.63, 0.89) | 1, 3, 4, 5, 6, 8, 14, 15, 17, 19, 25 | 6 |
| Ericson et al. ( | Sweden | 45–74 | M/F: 25,069 | 17 | MDC | 3588 | WG | Baseline FFQ | T3 versus T1 | 0.89 (0.82–0.96) | 1, 2, 4, 5, 6, 9,17, 18, 25, 27 | 8 |
| Kyrø et al. ( | Denmark | 50–65 | M/F: 55,465 | 15 | DCH | 7417 | WG | Baseline FFQ | Q4 versus Q1 | M:0.80(0.73,0.88) F: 0.85(0.77,0.94) | 4, 5, 6, 12, 17, 26 | 7 |
| Hu et al. ( | United States | 30–55 | F: 69,139 | 30 | NHS | 8170 | WG | Repeated FFQ | C5 versus C1 | 0.68(0.63, 0.73) | 1, 3, 5, 6, 7, 8, 13, 14, 15, 16 | 7 |
| Hu et al. ( | United States | 25–42 | F: 89,120 | 26 | NHS II | 7072 | WG | Repeated FFQ | C5 versus C1 | 0.73 (0.68, 0.80) | 1, 3, 5, 6, 7, 8, 13, 14, 15, 16. | 7 |
| Hu et al. ( | United States | 40–75 | M: 36,525 | 30 | HPFS | 3387 | WG | Repeated FFQ | C5 versus C1 | 0.72 (0.64, 0.81) | 1, 3, 5, 6, 7, 8, 13, 14, 15, 16 | 7 |
Abbreviations: BMI, body mass index; BWHS, Black Women's Health Study; C, category; CI, confidence interval; DCH, Danish Diet, Cancer, and Health cohort; EPIC‐Postdom study, European Prospective Investigation into Cancer and Nutrition; F, female; FFQ, food frequency questionnaire; FPS, Finnish prospective study; HPFS, health professional follow‐up study; HR, hazard ratio; lWHS, Iowa Women's Health Study; M, male; MDC, Malmö Diet and Cancer Study; NHS I, nurse health study I; NHS II, nurse health study II; NOS, Newcastle‐Ottawa Scale; Q, quintile or quartile; T, tertile; TEE, total energy intake; WG, whole grain.
Adjusted factors codes: 1 – Age, 2 – sex, 3 – Race/Ethnicity, 4 – BMI, 5 – Smoking status, 6 – Alcohol intake, 7 – Multivitamin use, 8 – Physical activity, 9 – Leisure time physical activity, 10 – Sports activity, 11 – Strenuous physical activity, 12 – Cambridge physical activity index, 13 – Modified alternative healthy eating index, 14 – Family history of diabetes, 15 – Postmenopausal hormone use for women, 16 – Oral contraceptive use for women, 17 – Education level, 18 – Season, 19 – Income, 20 – Blood pressure, 21 – Waist circumference, 22 – waist‐to‐hip ratio, 23 – Occupational activity, 24 – Geographic area, 25 – TEE, 26 – Red and processed meat intake, 27 – Dietary variables (according to dietary method version), 28 – butter, margarine and vegetable fat, 29 – Coffee consumption, 30 – Sugar‐sweetened soft drink consumption, 31 – Low‐fat dairy consumption, 32 – Fruit and berries, and vegetables.
FIGURE 2Relative risk and 95% confidence intervals (CIs) of type 2 diabetes for the highest compared to the lowest category of whole grain consumption. The black square and horizontal line represent the study‐specific HR and 95% CI, respectively; the area of the black square is proportional to the specific‐study weight to the overall meta‐analysis. The center of the open diamond presents the pooled HR and its width represents the pooled 95% CI. Weights are from random‐effects analysis
Whole grain intake and the risk of type 2 diabetes (highest compared with the lowest category meta‐analysis)
| Comparison | Highest versus lowest category | Dose–response (per 50 g/d) | ||||
|---|---|---|---|---|---|---|
| No | RR (95%CI) |
| No | RR (95%CI) |
| |
| Sex | ||||||
| Men | 1 | 0.72 (0.64, 0.81) | 0 | 1 | 0.67 (0.59, 0.76) | 0 |
| Women | 5 | 0.74 (0.66, 0.81) | 41.0% (.001) | 5 | 0.72 (0.59, 0.89) | 97% (<.001) |
| Both | 5 | 0.87 (0.77, 0.97) | 48.6% (.03) | 4 | 0.89 (0.80, 0.97) | 72.1% (.01) |
| Region | ||||||
| USA | 6 | 0.73 (0.68, 0.79) | 26.3% (<.001) | 6 | 0.71 (0.60, 0.86) | 96.4% (<.001) |
| Europe | 5 | 0.87 (0.77, 0.97) | 48.6% (.03) | 4 | 0.89 (0.81, 0.97) | 72.1% (.01) |
| Number of cases | ||||||
| <3000 | 5 | 0.84 (0.71, 0.99) | 36% (.05) | 4 | 0.86 (0.75, 0.98) | 82.8% (.001) |
| >3000 | 6 | 0.76 (0.68, 0.85) | 83.5% (.002) | 6 | 0.73 (0.61, 0.86) | 96.2% (<.001) |
| Follow‐up duration | ||||||
| <10 years | 5 | 0.83 (0.71, 0.97) | 48% (.03) | 5 | 0.88 (0.80, 0.96) | 79% (.001) |
| >10 years | 6 | 0.76 (0.67, 0.86) | 83.6% (.003) | 5 | 0.77 (0.69, 0.87) | 96% (<.001) |
| Assessment method adjustments | ||||||
| Baseline FFQ | 5 | 0.86% (0.78, 0.96) | 47.2% (.02) | 4 | 0.90 (0.84, 0.96) | 69.1% (.02) |
| Repeated FFQ | 6 | 0.72% (0.67, 0.78) | 15.8% (<.001) | 6 | 0.68 (0.55, 0.85) | 96% (<.001) |
| Energy intake | ||||||
| Yes | 6 | 0.85 (0.76, 0.95) | 40.1% (.01) | 5 | 0.90 (0.84, 0.96) | 77.1% (.002) |
| No | 5 | 0.74 (0.66, 0.82) | 72.3% (.002) | 5 | 0.65 (0.53, 0.80) | 92.7% (<.001) |
| BMI | ||||||
| Yes | 8 | 0.84 (0.78, 0.91) | 35.6% (.001) | 7 | 0.88 (0.82, 0.93) | 76.2% (<.001) |
| No | 3 | 0.70 (0.63, 0.79) | 0% (.006) | 3 | 0.59 (0.49, 0.71) | 86% (.001) |
| Family history of T2D | ||||||
| Yes | 6 | 0.72 (0.67, 0.78) | 15.8% (<.001) | 6 | 0.68 (0.55, 0.85) | 96% (<.001) |
| No | 5 | 0.86 (0.78, 0.96) | 47.2% (.02) | 4 | 0.90 (0.85, 0.96) | 69.1% (.02) |
| Alcohol consumption | ||||||
| Yes | 9 | 0.79 (0.72, 0.86) | 81.3% (<.001) | 9 | 0.78 (0.69, 0.89) | 95% (<.001) |
| No | 2 | 0.69 (0.50, 0.96) | 0% (.80) | 1 | 0.73 (0.52, 1.02) | – |
Abbreviations: BMI, Body Mass Index; FFQ, Food Frequency Questionnaire; No, number; USA, United States.
Number of included studies for highest versus lowest analysis.
Number of included studies for linear dose–response analysis.
FIGURE 3Dose–response analysis of risk of type 2 diabetes and whole grain consumption. The solid line and the long‐dashed line represent the estimated HR and its 95%CI; the solid line represents the linear relation